Materials and Methods: This was a retrospective noncomparative study. Forty-three eyes of 23 patients (17 female, 6 male) were evaluated. Patients with sarcoid-associated uveitis were systematically followed at least 6 months after initiation of low-dose oral MTX 10 (7.5-12.5) mg/week for 6-9 months. Inclusion criteria were non-responsiveness to steroid treatment or intolerance to these drugs. Visual acuity, anterior chamber inflammation, vitritis, papillitis, choroidal involvement, vasculitis, and macular edema were used to evaluate the efficacy of MTX therapy. Initial results and last follow-up findings were compared.

Results: The study was carried out on a total of 43 cases . The age of the patients ranged between 32 and 75 years with an average of 52.40±13.14 years. We found a statistically significant 0.54±0.35 unit increase in the mean visual acuity of the patients after treatment (p<0.01). There was also a significant 3.14±1.14 unit decrease in the number of attacks after treatment (p<0.01). Another significant difference was in the rate of cystoid macular edema when compared between pre and post steroid therapy. (p<0.01). The number of 24 (%55.8) cases with cystoid macular edema decreased to 8 cases (18.6%) after additional steroid treatment and statistically this reduction was found to be very significant. There was only one recurrence during follow-up.

Conclusion: Low-dose MTX therapy was effective and safe in the treatment of sarcoid-associated uveitis. Nevertheless, we need additional agents for macular edema. Keywords : Sarcoid uveitis, macular edema, methotrexate